A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery

PI: Giuseppe Lo Russo

This trial is testing MK-2870 in combination with pembrolizumab (Pembro) after surgery in people with newly diagnosed non-small cell lung cancer (NSCLC).  

The drugs he or she will receive will depend on whether he or she has had surgery before this trial and the type of NSCLC he or she has. 

If she has not had surgery for NSCLC before starting the trial she will receive pembro and chemotherapy for up to 12 weeks. Afterwards you may have surgery to remove your NSCLC. 

If you had surgery for NSCLC before starting the trial you will receive the trial treatment: 

• Group 1: will receive MK-2870 plus pembro  
• Group 2: will receive pembro